Ionis Pharmaceutics shares are trading higher after the company announced that the FDA accepted olezarsen FCS New Drug Application for Priory Review. Also, the company completed enrollment in its Phase 3 sHTG program.
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceutics shares are trading higher after the FDA accepted olezarsen FCS New Drug Application for Priory Review. Additionally, the company completed enrollment in its Phase 3 sHTG program.
June 25, 2024 | 5:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ionis Pharmaceutics shares are trading higher following the FDA's acceptance of the olezarsen FCS New Drug Application for Priory Review and the completion of enrollment in its Phase 3 sHTG program.
The FDA's acceptance of the New Drug Application is a significant regulatory milestone that can lead to market approval, boosting investor confidence. Additionally, the completion of Phase 3 enrollment indicates progress in their clinical trials, further supporting a positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100